Catalyst Wire Dossier Catalyst Wire Dossier

BMS-790052

daclatasvir · Bristol-Myers Squibb
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BMS-790052, covering 2015-10-09 to 2015-10-12. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment [Phase 2]

See pricing